COVID-19, Hydroxychloroquine, and the Promise of Clinical Trials

By | Clinical Trials

As the scientific community races to establish treatment regimens for COVID-19, clinical trials have been thrust into the spotlight as clinicians and policymakers alike seek data to inform their decisions. The ability to interpret clinical trial data and expedite new clinical trials will be critical in obtaining and leveraging key insights on how to manage this pandemic.   Hydroxychloroquine has garnered much attention in this regard. It is currently approved in the United States for the treatment of malaria, lupus, and rheumatoid arthritis. While preclinical data suggest that hydroxychloroquine is an inhibitor of COVID-19 within in vitro cell lines1, the…

Read More